Skip to content
TriangleGet started
← Full study record

NCT06039384 · OUTCOME

Kaplan-Meier Estimate of ≥6-month and ≥12-month Progression-free Survival (PFS)

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation · Source last updated 2026-09-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage probability
Interval / dispersion
95% Confidence Interval
Time frame
≥6-months and ≥12-months (up to 470 days)

What was measured

≥6-month and ≥12-month PFS was defined as the absence of disease progression (assessed per RECIST v1.1 by the investigator) or death from any cause from the start of treatment to ≥6 or ≥12 months after treatment. A Kaplan-Meier estimate of PFS is an estimate of the probability that a participant will remain alive and free from disease progression (or relapse) at a given time point after starting treatment.

Analysis population: Full Analysis Set. PFS rates were estimated using the Kaplan-Meier method. Confidence intervals for PFS rates were calculated using the Greenwood formula with log-log transformation.

Groups in this outcome

INCB099280 50 mg QD Plus Adagrasib 400 mg BID

Participants received INCB099280 50 milligrams (mg) once daily (QD) plus adagrasib 400 mg twice daily (BID) for up to 2 years.

INCB099280 100 mg BID Plus Adagrasib 400 mg BID

Participants received INCB099280 100 mg BID plus adagrasib 400 mg BID for up to 2 years.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
INCB099280 50 mg QD Plus Adagrasib 400 mg BID3
INCB099280 100 mg BID Plus Adagrasib 400 mg BID3

Reported measurements

Kaplan-Meier estimated probability of PFS ≥6 months
Values in percentage probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
INCB099280 50 mg QD Plus Adagrasib 400 mg BID100.0Not reportedNANAVariance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.
INCB099280 100 mg BID Plus Adagrasib 400 mg BID0.0Not reportedNANAVariance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.
Kaplan-Meier estimated probability of PFS ≥12 months
Values in percentage probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
INCB099280 50 mg QD Plus Adagrasib 400 mg BID100.0Not reportedNANAVariance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.
INCB099280 100 mg BID Plus Adagrasib 400 mg BID0.0Not reportedNANAVariance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Variance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        100.0
      2. comment
        Variance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        0.0
    title
    Kaplan-Meier estimated probability of PFS ≥6 months
  2. categories
    1. measurements
      1. comment
        Variance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        100.0
      2. comment
        Variance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        0.0
    title
    Kaplan-Meier estimated probability of PFS ≥12 months
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    units
    Participants
description
≥6-month and ≥12-month PFS was defined as the absence of disease progression (assessed per RECIST v1.1 by the investigator) or death from any cause from the start of treatment to ≥6 or ≥12 months after treatment. A Kaplan-Meier estimate of PFS is an estimate of the probability that a participant will remain alive and free from disease progression (or relapse) at a given time point after starting treatment.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received INCB099280 50 milligrams (mg) once daily (QD) plus adagrasib 400 mg twice daily (BID) for up to 2 years.
    id
    OG000
    title
    INCB099280 50 mg QD Plus Adagrasib 400 mg BID
  2. description
    Participants received INCB099280 100 mg BID plus adagrasib 400 mg BID for up to 2 years.
    id
    OG001
    title
    INCB099280 100 mg BID Plus Adagrasib 400 mg BID
param Type
NUMBER
population Description
Full Analysis Set. PFS rates were estimated using the Kaplan-Meier method. Confidence intervals for PFS rates were calculated using the Greenwood formula with log-log transformation.
reporting Status
POSTED
time Frame
≥6-months and ≥12-months (up to 470 days)
title
Kaplan-Meier Estimate of ≥6-month and ≥12-month Progression-free Survival (PFS)
type
SECONDARY
unit Of Measure
percentage probability

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Independent clinical review pending · Not medical advice